期刊文献+

应用高通量可复用透析器透析对尿毒症患者血清蛋白丢失的观察 被引量:1

Observation of serum protein loss in uremia patients treated with high-flux and reprocessable dialyzer
下载PDF
导出
摘要 目的观察普通血液透析(HD),血液透析滤过(HDF)及可复用高通量血液透析(HFDR)治疗的尿毒症患者血清中蛋白质丢失情况。方法选择北京市中关村医院长期血液透析患者52例,将患者随机分为HD组(n=20)、HDF组(n=20)及HFDR组(n=12),前瞻性对照观察各组患者治疗中排出液蛋白含量及HD、HFDR治疗半年及一年后血清白蛋白量。结果①HD组排出液中蛋白浓度(1.14±0.52)mg/dl低于HFDR(1.37±0.45)mg/dl组(P<0.05);②HFDR组排出液中蛋白浓度(1.37±0.45)mg/dl明显低于HDF组(3.39±1.60)mg/dl(P<0.01);③应用全自动透析器复用机复用高通量透析器二十次内,排出液蛋白浓度无明显变化(P>0.05);④常规HD及应用HFDR治疗半年、一年后两组患者血清白蛋白浓度无明显差异[HD:(37.97±2.54)mg/dl比(36.69±1.84)mg/dl;HFDR(37.83±2.13)mg/dl比(37.26±2.46)mg/dl](P>0.05)。结论常规HD有微量蛋白丢失;HFDR在规定复用次数内不会造成蛋白质的过多丢失、不会引起血清白蛋白下降;HDF有较大量蛋白质的丢失。 Objective To observe serum protein loss in uremia patients treated with conventional hemodialysis (HD), hemodiafiltration (HDF) and high-flux dialysis reprocessing (HFDR). Methods We recruited 52 uremia patients treated with maintenance hemodialysis in Beijing Zhong Guan Cun Hospital, and randomly divided them into HD group (n=20), HDF group (n=20) and HFDR group (n=12). We prospectively observed protein content in discharged fluid in the 3 groups, and serum albumin change after HD and HFDR for half a year and one year. Results (a) Protein concentration in discharged fluid was lower in HD group (1.14 ± 0.52 mg/dl) than in HFDR group (1.37 ±0.45 mg/dl, P 〈 0.05), and the concentration in HFDR group was significantly lower than that in HDF group (3.39 ±1.60mg/all, P 〈 0.01). (b) Protein concentration in discharged fluid did not change significantly if the high-flux dialyzer was reused for less than 20 times after reprocessing by the automatic dialyzer reprocessing machine (P 〉 0.05). (c) After the treatment for half a year and one year, no significant differences in serum albumin was found between HD group (half a year, 37. 97 ± 2.54 mg/dl; one year, 36.69 ±1.84 mg/dl) and HFDR group (half a year, 37.83 ±2.13 mg/dl; one year, 37.26 ±2.46mg/dl, P 〉 0.05). Conclusions Conventional HD therapy causes less protein loss. HFDR may not result in excess protein loss and decrease of serum albumin, if the dialyzer was reused within permissible times. HDF causes more protein loss.
出处 《中国血液净化》 2009年第10期547-549,共3页 Chinese Journal of Blood Purification
关键词 血液透析 血液透析滤过 可复用高通量血液透析 蛋白质 Hemodialysis Hemodiafiltration High flux dialysis reprocessing Protein loss
  • 相关文献

参考文献4

二级参考文献38

  • 1龚德华,季大玺,谢红浪.高通量透析器复用的研究[J].医学研究生学报,2000,13(5):307-310. 被引量:26
  • 2Acchiardo S. Beta 2-microglobulin, amyloidosis, and dialysis. [J]. Int J Artif Organs, 1988, 11:229-31.eview.
  • 3佐中牧,秋叶隆主编,庞宝珍等编译.透析疗法:最新透析疗法专家解疑[M].军事医学科学出版社,1998.11.1.
  • 4陈香美主编.现代慢性肾衰治疗学[M].北京:人民军医出版社,2000.2:30.
  • 5Tokars JI, Miller ER, Alter MJ, et al. National surveillance of dialysis associated diseases in the United States[J]. Semin Dial. 2000;13:75-85.
  • 6Sethi D, Gower PE, Dialysis arthropathy, beta 2-microglobulin and the effect of dialyser membrane[J]. Nephrol Dial Transplant, 1988,3:768-72.
  • 7Jacobs C, Kjellstrand CM, Koch KM, Winchester JF ( Editor-inchief). Keplacement of renal function by dialysis. 4th Revised Edition, Mrtherland: Lluwer Academic publisher, 1996:432
  • 8Ley poldt JK, Cheung AK, Clark WR, et al. Characterization of low and high-flux dialyzers NIH HEMO study: Interim report(Abstract).J Am Soc Nephrol, 1996,7:1518.
  • 9K linkmann H. , Vienken J . Membranes of dialysis. Nephrol Dia Transplant, 1995, (10) S3:39.
  • 10Leto E, Bilal F, Osmic I. Efficiency of high-flux dialysis in removal of beta-microglobulin. Med Ash, 2001,55(4) :225.

共引文献163

同被引文献31

  • 1吴平勇,张庆红,张建鄂,李涛,张永,王顺华,李新华.高通量透析可改善维持性血液透析患者肾性贫血[J].生物医学工程与临床,2005,9(1):40-44. 被引量:9
  • 2许传文.高通量透析对血β_2微球蛋白浓度及蛋白质浓度的影响[J].临床内科杂志,2005,22(6):424-425. 被引量:1
  • 3Eknoyan G, Beck G J, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis [ J ]. N Engl J Med, 2002, 347 (25) : 2010-2019.
  • 4Malyszko JS, Malyszko J, Hryszko T, et al. Markers of endothelial damage in patients on hemodialysis and hemodiafiltration [ J ]. J Nephrol, 2006, 19(2): 150-154.
  • 5Raggi P, Vukicevic S, Moyses RM, et al. Ten-year experience with sevelamer and calcium salts as phosphate binders [ J ]. Clin J Am Soc Nephrol, 2010, 5 (Suppl 1 ) : $31-$40.
  • 6Penne EL, van der Weerd NC, Grooteman MP, et al. Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients [ J ]. Clin J Am Soe Nephrol, 2011, 6(2) : 281-289.
  • 7Kong X, Zhang L, Zhang L, et al. Mineral and bone disorder in Chinese dialysis patients: a muhicenter study [ J ]. BMC Nephrology, 2012, 13 : 116.
  • 8Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population [ J ]. Nephrol Dial Transplant, 2011, 26 ( 6 ) : 1948- 1955.
  • 9Shidara K, Inaba M, Okuno S, et al. Influence of nutritional status on serum large N-truncated PTH, but not PTH (1-84) in hemodialysis patients [ ]]. Biomed Pharmacother, 2007,61 (2/3) : 142-147.
  • 10Lugon JR, Andre ME, Duarte ME, et al. Effects of incenter daily hemodialysis upon mineral metabolism and bone disease in end-stage renal disease patients [J]. Sao Paulo Med J, 2001, 119(3) : 105- 109.

引证文献1

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部